Lung Kee (Bermuda) Holdings Limited (HK:0255)
:0255
Top Page
Lung Kee (Bermuda) Holdings Limited
(0255)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$1.50
▼(-9.09% Downside)
Action:ReiteratedDate:04/11/26
Overall score reflects (1) mixed financial performance—strong balance sheet and positive operating cash flow but persistent losses and declining revenue, (2) a mildly positive near-term technical picture constrained by weaker long-term trend, and (3) valuation support from a very high dividend yield, tempered by a negative P/E driven by ongoing losses.
Positive Factors
Low leverage / strong balance sheet
A near-zero debt-to-equity profile gives the company durable financial flexibility to fund operations, capex, and working capital during downturns. Low leverage materially reduces solvency risk, enabling strategic responses and supporting long-term operational continuity even while earnings recover.
Negative Factors
Multi-year net losses
Three consecutive years of net losses indicate persistent profitability shortfalls. Continued operating deficits constrain retained earnings, limit reinvestment capacity, and require reliance on cash reserves or asset sales to maintain dividends or capex, weakening long-term earnings credibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A near-zero debt-to-equity profile gives the company durable financial flexibility to fund operations, capex, and working capital during downturns. Low leverage materially reduces solvency risk, enabling strategic responses and supporting long-term operational continuity even while earnings recover.
Read all positive factors
Lung Kee (Bermuda) Holdings Limited (0255) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$950.83M
Dividend Yield14.77%
Average Volume (3M)41.87K
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue Growth-4.52%
EPS GrowthN/A
CountryHK
Employees3,000
SectorIndustrials
Sector Strength72
IndustryManufacturing - Metal Fabrication
Share Statistics
EPS (TTM)-0.03
Shares Outstanding633,887,300
10 Day Avg. Volume75,200
30 Day Avg. Volume41,866
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.70
Price to Sales (P/S)0.82
P/FCF Ratio6.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lung Kee (Bermuda) Holdings Limited Business Overview & Revenue Model
Company Description
Lung Kee (Bermuda) Holdings Limited, an investment holding company, manufactures and markets mold bases and related products in the People's Republic of China and internationally. The company was founded in 1975 and is headquartered in Sha Tin, Ho...
How the Company Makes Money
null...
Lung Kee (Bermuda) Holdings Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
82
Very Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.32B | 1.55B | 1.45B | 1.60B | 2.27B |
| Gross Profit | 268.35M | 951.69M | 263.90M | 398.00M | 777.07M |
| EBITDA | 108.90M | 148.58M | 56.87M | 180.74M | 472.05M |
| Net Income | -22.62M | -13.67M | -72.43M | 15.81M | 227.84M |
Balance Sheet | |||||
| Total Assets | 1.82B | 1.97B | 2.09B | 2.30B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 588.63M | 546.65M | 428.76M | 536.64M | 833.59M |
| Total Debt | 4.36M | 7.83M | 6.57M | 9.56M | 9.02M |
| Total Liabilities | 266.93M | 298.08M | 294.22M | 314.90M | 474.46M |
| Stockholders Equity | 1.55B | 1.67B | 1.80B | 1.99B | 2.27B |
Cash Flow | |||||
| Free Cash Flow | 173.25M | 190.82M | -35.72M | -93.17M | 168.61M |
| Operating Cash Flow | 213.28M | 226.34M | 77.21M | 89.17M | 369.94M |
| Investing Cash Flow | -27.03M | -24.35M | -98.07M | -170.05M | -193.03M |
| Financing Cash Flow | -165.69M | -67.33M | -73.86M | -168.90M | -277.76M |
Lung Kee (Bermuda) Holdings Limited Technical Analysis
Positive
1.65
Price Trends
1.46
Positive
1.59
Negative
1.58
Negative
Market Momentum
0.01
Negative
54.14
Neutral
45.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0255, the sentiment is Positive. The current price of 1.65 is above the 20-day moving average (MA) of 1.48, above the 50-day MA of 1.46, and above the 200-day MA of 1.58, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.14 is Neutral, neither overbought nor oversold. The STOCH value of 45.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0255.
Lung Kee (Bermuda) Holdings Limited Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$1.51B | 2.76 | 7.79% | 2.71% | 28.78% | 185.71% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | HK$1.42B | 3.27 | 7.83% | 5.09% | 0.51% | 3.74% | |
62 Neutral | HK$950.83M | -47.78 | -1.44% | 14.77% | -4.52% | ― | |
61 Neutral | HK$4.65B | 11.95 | 18.58% | 1.81% | 10.34% | 3.48% | |
54 Neutral | HK$610.31M | 69.30 | 0.61% | ― | 1.48% | 12.50% | |
52 Neutral | HK$268.13M | -12.33 | -4.33% | ― | 10.91% | 11.01% |
* Industrials Sector Average
HK:0255
Lung Kee (Bermuda) Holdings Limited
1.50
0.36
31.58%
HK:0822
Ka Shui International Holdings Limited
0.30
0.04
17.65%
HK:0838
Eva Precision Industrial Holdings Limited
0.82
0.08
10.51%
HK:0929
IPE Group Limited
0.58
0.16
38.10%
HK:1050
Karrie International Holdings Limited
2.23
1.54
223.19%
HK:3816
KFM Kingdom Holdings Ltd.
2.51
2.20
714.94%
Lung Kee (Bermuda) Holdings Limited Corporate Events
Lung Kee Calls 2026 AGM, Seeks Share Issue Mandate and Board Re-elections
Apr 2, 2026
Lung Kee Group Holdings Limited has called its annual general meeting for 18 May 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend. The meet...
Lung Kee Group Declares Final HKD 0.12 Dividend for 2025
Mar 20, 2026
Lung Kee Group Holdings Limited has declared a final ordinary cash dividend of HKD 0.12 per share for the financial year ended 31 December 2025, subject to shareholder approval on 18 May 2026. The dividend will be paid in Hong Kong dollars on 9 Ju...
Lung Kee widens annual loss as revenue falls but posts positive comprehensive income
Mar 20, 2026
Lung Kee Group Holdings Limited reported a decline in full-year 2025 revenue to HK$1.32 billion from HK$1.55 billion in 2024, reflecting softer demand and pressure on its core manufacturing operations. The group’s loss for the year widened t...
Lung Kee Group Sets March Board Meeting to Approve 2025 Results and Final Dividend Plan
Mar 5, 2026
Lung Kee Group Holdings Limited has scheduled a board meeting for 20 March 2026 in Hong Kong to review and approve the audited final results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.